Search

everythinglearnresearchcommunity

for

Search:↓

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Eclipta alba IIHR Sel EA 43 is best for large-scale cultivation due to high growth, yield, and wedelolactone content.

The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

Erlotinib can cause unexpected side effects like eyelash growth and scarring.

ERULUS controls root hair growth by regulating cell wall composition and pectin activity.

ERULUS is crucial for root hair growth by controlling calcium levels.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Eclipta alba may improve memory and help treat Alzheimer's disease.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Eclipta alba can effectively kill worms like the drug Albendazole.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

EREG therapy may help treat hair loss by promoting hair growth.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

LLPS is crucial for RALF signaling, aiding plant growth and stress resilience.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

Ritlecitinib is safe and may effectively treat alopecia areata.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

PLD is an effective and safer alternative for treating breast cancer.

Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.